| Literature DB >> 35052382 |
Ernesto Picardi1,2,3, Luigi Mansi1, Graziano Pesole1,2,3.
Abstract
ADAR1-mediated deamination of adenosines in long double-stranded RNAs plays an important role in modulating the innate immune response. However, recent investigations based on metatranscriptomic samples of COVID-19 patients and SARS-COV-2-infected Vero cells have recovered contrasting findings. Using RNAseq data from time course experiments of infected human cell lines and transcriptome data from Vero cells and clinical samples, we prove that A-to-G changes observed in SARS-COV-2 genomes represent genuine RNA editing events, likely mediated by ADAR1. While the A-to-I editing rate is generally low, changes are distributed along the entire viral genome, are overrepresented in exonic regions, and are (in the majority of cases) nonsynonymous. The impact of RNA editing on virus-host interactions could be relevant to identify potential targets for therapeutic interventions.Entities:
Keywords: ADAR; RNA editing; SARS-COV-2; transcriptome
Mesh:
Substances:
Year: 2021 PMID: 35052382 PMCID: PMC8774467 DOI: 10.3390/genes13010041
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Figure 1RNA editing and expression of key genes in total RNAseq data from Calu-3 infected cells at three time points post-infection (4 h, 12 h, and 24 h). (A) Distribution of hyper-edited reads identified in infected Calu-3 cells in which A-to-G and T-to-C events appear prominent. (B) Nucleotide context one nucleotide upstream and downstream the detected hyper-edited sites. (C) Gene expression of type-I interferon (IFNB1) and key sensor genes, DDX58 (RIG-I) and IFIH1 (MDA5), in infected Calu-3 cells. Here, we report only IFNB1 as main interferon gene modulated upon infection. As expected, DDX58 and IFIH1 increase their expression during the infection. Gene expression of type-I interferons, RIG-I and TLR receptors, and APOBECs are reported in the Supplementary Figure S1A. (D) Expression of ADAR1 (ADAR) and ADAR2 (ADARB1) genes in infected Calu-3 cells. While ADAR2 is expressed at extremely low levels and does not change during the infection, ADAR1 is positively modulated and its expression increases significantly (DESeq2 adjusted p-value < 0.05) from 4 to 12 h post-infection. (E) Enrichment of unique hyper editing positions in infected Calu-3 cells. (F) Alu editing index (AEI) in infected Calu-3 cells. It is a reliable score to measure the ADAR activity at the transcriptome level and tends to grow with the increase in ADAR expression. Dotted lines and bars on each dot indicate mean gene expression or AEI ± SD.
Figure 2RNA editing and expression of key genes in RNAseq data from infected (inf) and uninfected (ctrl) Vero cells. (A) Gene expression of type-I interferon (IFNB1) and key sensor genes, DDX58 (RIG-I) and IFIH1 (MDA5) in Vero cells. Here, we report the expression of IFNB1 as representative gene of type-I interferons. Although IFIH1 were up-regulated, type-I interferons are not modulated. (B) Expression of ADAR1 (ADAR) and ADAR2 (ADARB1) genes in Vero cells. Although ADAR1 is downregulated in infected cells (DESeq2 adjusted p-value < 0.05), it is expressed in all samples. ADAR2 is also expressed in all samples but at very low levels. (C) Enrichment of unique hyper editing positions in Vero cells. (D) Distribution of hyper-edited reads identified in infected Vero cells. A-to-G and T-to-C events outnumber other substitution types. (E) Nucleotide context one base upstream and downstream the detected hyper-edited sites.
RNA editing in clinical samples. Here, we report the total number of RNA editing events found at single-nucleotide levels as well as the number and fraction of hyper-edited reads. For each sample, we include the BioProject and run accession, the sampling source, the virus load and genomic depth, the fraction of A-to-I and C-to-U RNA editing events, and the number of hyper-edited reads. Further statistics are in Supplementary Table S1. # This character means percentage of hyper not A-to-I reads.
| BioProject | Run | Source | Virus Load | Depth | RNA Editing (All Events) | % A-to-I | % no A-to-I | % C-to-U | % no C-to-U | # Hyper A-to-I Reads | # Hyper non A-to-I Reads | % Hyper A-to-I Reads |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRJNA616446 | SRR11454606 | Throat swab | 0.03 | 9.64 | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PRJNA616446 | SRR11454607 | Faeces | 0.24 | 62.53 | 1 | 100.00 | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 |
| PRJNA616446 | SRR11454608 | Throat swab | 3.27 | 610.55 | 21 | 57.14 | 42.86 | 38.10 | 61.90 | 0.00 | 0.00 | 0.00 |
| PRJNA616446 | SRR11454612 | Sputum | 0.08 | 13.76 | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PRJNA616446 | SRR11454613 | BALF | 8.33 | 2256.34 | 1836 | 89.43 | 10.57 | 8.66 | 91.34 | 4.00 | 0.00 | 100.00 |
| PRJNA616446 | SRR11454614 | BALF | 18.39 | 4167.78 | 6270 | 84.74 | 15.26 | 13.11 | 86.89 | 2.00 | 0.00 | 100.00 |
| PRJNA616446 | SRR11454615 | BALF | 1.21 | 321.73 | 18 | 50.00 | 50.00 | 27.78 | 72.22 | 0.00 | 0.00 | 0.00 |
| PRJNA605907 | SRR11059940 | BALF | 95.36 | 21.06 | 1 | 0.00 | 100.00 | 0.00 | 100.00 | 0.00 | 0.00 | 0.00 |
| PRJNA605907 | SRR11059941 | BALF | 65.44 | 1.42 | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PRJNA605907 | SRR11059942 | BALF | 93.56 | 478.34 | 286 | 89.51 | 10.49 | 6.99 | 93.01 | 1.00 | 4.00 | 20.00 |
| PRJNA605907 | SRR11059943 | BALF | 87.59 | 39.39 | 5 | 0.00 | 100.00 | 20.00 | 80.00 | 3.00 | 0.00 | 100.00 |
| PRJNA605907 | SRR11059944 | BALF | 94.33 | 1904.89 | 2779 | 84.02 | 15.98 | 12.20 | 87.80 | 3.00 | 1.00 | 75.00 |
| PRJNA605907 | SRR11059945 | BALF | 99.21 | 267.75 | 0 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PRJNA605907 | SRR11059946 | BALF | 99.05 | 5412.00 | 13,461 | 80.54 | 19.46 | 17.18 | 82.82 | 11.00 | 2.00 | 84.62 |
| PRJNA605907 | SRR11059947 | BALF | 94.11 | 7674.39 | 7480 | 76.67 | 23.33 | 21.38 | 78.62 | 59.00 | 14.00 | 80.82 |
| PRJNA601736 | SRR10903401 | BALF | 3.12 | 102.80 | 2 | 0.00 | 100.00 | 100.00 | 0.00 | 0.00 | 1.00 | 0.00 |
| PRJNA601736 | SRR10903402 | BALF | 9.35 | 429.91 | 13 | 53.85 | 46.15 | 30.77 | 69.23 | 0.00 | 9.00 | 0.00 |
Figure 3Genomic context of A-to-I RNA editing clusters detected in total RNAseq data from infected Calu-3 cells and Vero cells. We report also known SARS-COV-2 transcripts and putative RNA secondary structures from Rangan et al. [44]. A-to-I clusters in forward orientation are marked in blue, while clusters in reverse orientation are in red.